The World Health Organization (WHO) has approved China's Sinovac Covid vaccine for emergency use.
The WHO said it prevented symptomatic disease in 51% of those vaccinated and prevented severe symptoms and hospitalisation in 100% of samples.
Some evidence and data gaps are still lacking though, according to WHO experts.
It is the second Chinese vaccine to receive the green light from the WHO, after Sinopharm.
The approval opens the door for the jab to be used in the Covax programme, which aims to ensure fair access to vaccines.
The vaccine, which has already been used in several countries, has been recommended for over 18s, with a second dose two to four weeks later.
The emergency approval means the vaccine "meets international standards for safety, efficacy and manufacturing", the WHO said.
A study in a Brazilian city saw a 95% drop in Covid deaths after it vaccinated almost all of its adults with Sinovac.
Serrana, in the Southeastern Brazilian state of Sao Paulo, is home to 45,000 residents. Once 75% of its population was vaccinated, the number of cases and hospitalisations fell, according to the study.
Read the full article here.
Refana Inc., is United States registered private corporation dedicated to finding practical and innovative solutions to the world's medical problems. By utilizing a highly collaborative open source system of research and development Refana has been able to attract world leaders in their respective scientific and medical fields to work on these problems. Through this model Refana hopes to greatly accelerate the vaccine development process for Covid-19 and help protect not only the health of the world, but also the economies and stability of nations at risk.